$ compare sermorelin ipamorelin
Sermorelin vs Ipamorelin: How a GHRH Analogue and a GHRP Differ in the Research
Two GH secretagogues, two different receptors. Sermorelin works at the GHRH receptor; ipamorelin works at the separate ghrelin/GHS receptor. The mechanism contrast, read straight.
The short version
Sermorelin vs ipamorelin is a comparison of two different doors into the same room. Both make the pituitary release growth hormone, but they push different buttons. Sermorelin is a GHRH analogue — it copies the brain's natural "make GH" signal and works at the GHRH receptor. Ipamorelin is a GHRP (a growth-hormone-releasing peptide) — it works at a separate receptor, the ghrelin receptor, and was described as the first selective GH releaser, raising growth hormone without much effect on stress or prolactin hormones. Different mechanisms, often studied together.
Two receptors, two mechanisms
The core of sermorelin vs ipamorelin is receptor identity. Sermorelin is GHRH(1-29), a GHRH analogue that binds the GHRH receptor (GHRH-R) on pituitary somatotrophs and drives the cAMP/PKA pathway to release the body's own GH [15]. Ipamorelin belongs to the GHRP class — growth-hormone-releasing peptides that act on the ghrelin receptor (the growth-hormone-secretagogue receptor, GHS-R), a different protein entirely [15].
That distinction is why ipamorelin was characterized as the first selective GH secretagogue: it releases GH without significant effects on ACTH/cortisol or prolactin — a cleaner profile than earlier GHRPs, and a different mechanism from a GHRH analogue [15]. Sermorelin's selectivity sits elsewhere: because it acts through the native GHRH pathway, it preserves the somatostatin and IGF-1 feedback that shapes pulsatile GH release [4].
Why the two are studied together
Because the two receptors are independent, a GHRH analogue and a GHRP can act in a complementary, even synergistic, way on pituitary GH release. In older adults with low GH/IGF-1, low-dose GHRP-2 (a GHRP cousin of ipamorelin) augmented the GH response to GHRH(1-44)NH2, and chronic GHRP-2 for 30 days raised pulsatile GH and serum IGF-1 within 24 hours and kept it elevated [11].
The magnitude of that combined response is governed by non-peptide factors. Under a sex-steroid clamp, abdominal visceral fat, IGF-1 and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy in men — IGF-1 positively, visceral fat negatively [10]. These are studied combinations in the research literature, not a human dosing recommendation.
Half-life and the practical contrast
Native sermorelin is short-acting — a plasma half-life on the order of ~10-12 minutes, though a single dose keeps serum GH elevated for about 3 hours [3]. GHRPs likewise act as short-pulse secretagogues. The practical reading is that neither native sermorelin nor a short GHRP provides multi-day stimulation on its own; that property belongs to the DAC-extended GHRH analogues covered in sermorelin vs CJC-1295.
For a fuller view of sermorelin and the GH/IGF-1 axis, and the side-effect record for GHRH(1-29), see the research page. Nothing here is a protocol; it is a mechanism comparison drawn from the published literature.
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analogue acting on the GHRH receptor; ipamorelin is a GHRP/secretagogue acting on the separate ghrelin (GHS) receptor [15]. Ipamorelin was characterized as the first selective GH secretagogue, releasing GH without significant effects on ACTH/cortisol or prolactin — a different mechanism from a GHRH analogue [15]. They are often studied in combination because the two receptor pathways are complementary [11].